Search results for "Guidelines."

showing 10 items of 611 documents

The impact of galactooligosaccharides on the bioaccessibility of sterols in a plant sterol-enriched beverage: adaptation of the harmonized INFOGEST d…

2018

The effect of the addition of galactooligosaccharides (GOS) on sterol bioaccessibility in three plant sterol (PS)-enriched milk-based fruit beverages (without GOS addition (MfB) and with 2.5 g (MfB-G2) and 5.0 g (MfB-G5) GOS per 250 mL) was evaluated after micellar gastrointestinal digestion. Cholesterol bioaccessibility was very similar among beverages, though a slight significant increase (from 80% to 85%) was observed by the addition of 5.0 g GOS. The addition of GOS did not affect total PS bioaccessibility (≈37%). Based on the results obtained after micellar digestion, it has been demonstrated that these beverages could be a suitable food matrix for simultaneous enrichment with PS and G…

0301 basic medicinefood.ingredientFood technologyGuidelines as TopicIn Vitro TechniquesMicelleModels BiologicalMatrix (chemical analysis)Bile Acids and SaltsCholesterol Dietary03 medical and health scienceschemistry.chemical_compoundfoodGastrointestinal AgentsAnimalsHumansFood scienceMicellesGlycoproteinsFoods SpecializedGastrointestinal agent030109 nutrition & dieteticsbusiness.industryChemistryCholesterolFood additivePhytosterolsGeneral MedicineLipid DropletsInflammatory Bowel DiseasesSterolFruit and Vegetable JuicesCardiovascular DiseasesResearch DesignFood Technologylipids (amino acids peptides and proteins)DigestionFood AdditivesDairy ProductsGlycolipidsDigestionbusinessNutritive ValueTrisaccharidesFood ScienceFoodfunction
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

2019

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health c…

0301 basic medicinemedicine.medical_specialtyCognitiveGenital Neoplasms FemaleInternational Cooperation[SDV.CAN]Life Sciences [q-bio]/CancerCancer Chemotherapy Cognitive Gynecologic Offspring Pregnancy[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics03 medical and health sciencesGenital Neoplasms Female/therapyGynecologicOffspring0302 clinical medicineSDG 3 - Good Health and Well-beingPregnancyHealth caremedicinePrenatal Exposure Delayed Effects/etiologyHumansChemotherapyRadiation treatment planningIntensive care medicineSocieties MedicalCancerPregnancy Complications Neoplastic/therapyPregnancyVaginal deliverybusiness.industryCancerHematologymedicine.diseasePrognosis3. Good healthCancer registryLong-term care030104 developmental biologyOncology030220 oncology & carcinogenesisPrenatal Exposure Delayed EffectsPractice Guidelines as TopicFemalePractice Guidelines as Topic/standardsbusinessBreast feedingPregnancy Complications Neoplastic
researchProduct

Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.

2015

BACKGROUND There is still uncertainty about what constitutes the best therapeutic practice in ulcerative colitis (UC). OBJECTIVE The purpose of the "UC Horizons Project" was to raise a series of questions regarding the management of UC to provide responses based on the best scientific evidence available. METHODS The 11 members of the scientific committee prepared draft answers to the 10 questions from available evidence after a literature search. A total of 48 Spanish gastroenterology specialists nationwide participated in the project. The national meeting discussed the 10 issues in working groups and reached consensus regarding the recommendations by anonymous, interactive vote following t…

0301 basic medicinemedicine.medical_specialtyConsensusAttitude of Health PersonnelAlternative medicineDelphi methodGastroenterologyScientific evidence03 medical and health sciences0302 clinical medicineInternal medicinePhysiciansSurveys and QuestionnairesmedicineImmunology and AllergyHumansDisease management (health)Thiopurine methyltransferasebiologybusiness.industryRemission InductionGastroenterologyDisease ManagementEvidence-based medicineDiscontinuation030104 developmental biologyFamily medicinePractice Guidelines as Topicbiology.protein030211 gastroenterology & hepatologyColitis UlcerativeWorking groupbusinessInflammatory bowel diseases
researchProduct

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: …

2020

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treat…

0301 basic medicinemedicine.medical_specialtyESMO guidelinesDrug availability03 medical and health sciences0302 clinical medicineAdvanced diseaseAsian countryconsensuMedicineHCCReimbursementESMO guidelinePan-Asianbusiness.industryCancer conferenceRelapsed Hepatocellular CarcinomaHematologyhepatocellular carcinomaClinical Practice030104 developmental biologyOncologyconsensus030220 oncology & carcinogenesisFamily medicinebusiness
researchProduct

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology

2016

Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical g…

0301 basic medicinemedicine.medical_specialtyMEDLINEHigh dose intravenous immunoglobulin610 Medicine & healthEuropean Guidelines (S1) high-dose intravenous immunoglobulinDermatologySkin DiseasesDrug Administration Schedulelaw.inventionAutoimmune Diseases2708 Dermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawhemic and lymphatic diseasesintravenous immunoglobulinmedicineHumanshigh-doseEvidence-Based MedicineDose-Response Relationship Drugbusiness.industryDermatological diseases10177 Dermatology ClinicImmunoglobulins Intravenous2725 Infectious DiseasesEvidence-based medicinemedicine.diseaseDermatologyToxic epidermal necrolysisEuropeInfectious Diseases030104 developmental biologyEuropean Guidelines (S1)Dermatology clinicStevens-Johnson SyndromeInjections IntravenousEuropean Guidelines (S1) high-dose intravenous immunoglobulin dermatologyDrug MonitoringbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease.

2018

The diagnosis of Parkinson’s disease (PD) is based on clinical features and differently to the common opinion that detecting this condition is easy, seminal clinico-pathological studies have shown that up one-fourth of patients diagnosed as PD during life has an alternative diagnosis at post-mortem. The misdiagnosis is even higher when only the initial diagnosis is considered, since the diagnostic accuracy improves by time, during follow-up visits. Given that the confirmation of the diagnosis of PD can be only obtained through neuropathology, to improve and facilitate the diagnostic-therapeutic workup in PD, a number of criteria and guidelines have been introduced in the last three decades.…

0301 basic medicinemedicine.medical_specialtyParkinson's disease diagnostic criteriapreclinical Parkinson’s diseaseParkinson's diseaseParkinson’s disease guidelinesNeuropathologyDiseaseReviewlcsh:RC346-429prodromal Parkinson’s disease03 medical and health sciences0302 clinical medicinePreclinical Parkinson's diseasemedicineProdromal Parkinson's diseaseIntensive care medicinelcsh:Neurology. Diseases of the nervous systemJames Parkinsonbusiness.industryTask forceNoveltymedicine.diseaseClinical trial030104 developmental biologyNeurologyClinical diagnosisParkinson's disease guidelineParkinson’s disease diagnostic criteriaNeurology (clinical)Early phasebusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in neurology
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

2019

Background Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective, would be extremely beneficial. A pooled analysis of data for 12 834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the International Duration Evaluation of Adjuvant chemotherapy study, was carried out and the results presented at the ASCO Annual Meeting 2017. To clarify the potential impact of these results on clinical practice, ESMO decided to s…

0301 basic medicinemedicine.medical_specialtyTime FactorsColorectal cancerRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansMulticenter Studies as TopicColectomyNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryCAPOX RegimenHematologyCongresses as Topicmedicine.diseaseChemotherapy regimenOxaliplatinClinical trialOxaliplatinRegimen030104 developmental biologyOncologyClinical Trials Phase III as TopicChemotherapy Adjuvant030220 oncology & carcinogenesisData Interpretation StatisticalColonic NeoplasmsPractice Guidelines as TopicQuality of LifeNeurotoxicity Syndromesbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct